Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 17/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651071 | 0.92 | GCGR (0.56) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL27293870 | 0.87 | GCGR (0.49) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL9870958 | 0.83 | GCGR (0.72) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL5102048 | 0.82 | GCGR (0.70) | GCGR | |
| SCHEMBL9870499 | 0.82 | GCGR (0.47) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL8876019 | 0.81 | FABP3 (0.51) | GCGRFABP3FABP4FABP5 | |
| SCHEMBL8875946 | 0.81 | FABP3 (0.60) | GCGRFABP3FABP4FABP5 | |
| SCHEMBL8949663 | 0.80 | GCGR (0.61) | GCGRFABP3FABP4FABP5DPP4 | |
| SCHEMBL8879687 | 0.80 | FABP3 (0.50) | GCGRFABP3FABP4FABP5 | |
| SCHEMBL5098490 | 0.79 | GCGR (0.46) | GCGRFABP3FABP4FABP5DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7420059-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-02 | — | — | US | disclosed |
| US-20050171140-A1 | Prevent cholesterol biosynthesis; moderating blood serum lipid ; antidiabetic agents; obesity; hypotensive agents; osteoporosis; Alzheimer's disease; cardiovascular disorders; hormone replacement therapy | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171140-A1 | Prevent cholesterol biosynthesis; moderating blood serum lipid ; antidiabetic agents; obesity; hypotensive agents; osteoporosis; Alzheimer's disease; cardiovascular disorders; hormone replacement therapy | HMGCR, LDLR, APOB | GCGR 124/4885FABP3 234/4885FABP4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.